GENELUX Corp
GNLXNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | |
|---|---|---|---|---|
| Revenue | $8,000 | $8,000 | $170,000 | $11.1M |
| Operating income | −$33.2M | −$31.7M | −$24.2M | −$3.0M |
| Net income | −$32.1M | −$29.9M | −$28.3M | −$5.2M |
| Total assets | $19.0M | $34.7M | $27.9M | $5.5M |
| Total liabilities | $7.5M | $8.4M | $8.4M | $41.3M |
| Equity | $11.5M | $26.3M | $19.5M | −$35.8M |
| EPS (diluted) | $-0.86 | $-0.95 | $-1.16 | $-0.57 |
| Shares out. | 34.6M | 26.9M | 26.8M | 9.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −415175.0%
- Net margin
- −401812.5%
- Return on equity
- −278.5%
- Return on assets
- −168.9%
- Return on capital (ROCE)
- −259.4%
- Liabilities / assets
- 39.3%
- Debt / equity
- 0.65×
- Book value / share
- $0.33
- Revenue growth (YoY)
- 0.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -55.62distress
- Accruals / assets
- −36.1%clean
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Recruitingreadout ~2026-06Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- Phase 2Recruitingreadout ~2027-02Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Szalay AladarPassive (13G)Feb 17, 2026
- Armistice Capital, LlcPassive (13G)Nov 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 3.0M | 15.1 | -6.0% |
| Apr 30, 2026 | 3.1M | 24.3 | +4.2% |
| Apr 15, 2026 | 3.0M | 10.5 | -3.7% |
| Mar 31, 2026 | 3.1M | 15.0 | +9.9% |
| Mar 13, 2026 | 2.9M | 18.8 | -3.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreementMar 19, 2026
- Regulation FD disclosureFeb 2, 2026
- Other material eventJan 8, 2026
- Regulation FD disclosure · Other material eventJan 5, 2026
- Director / officer changeJan 2, 2026
- Director / officer change · Shareholder voteSep 3, 2025
- Other material eventMar 25, 2025
- Results of operations · Regulation FD disclosure · Other material eventMar 25, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.